REVOLUTION MEDICINES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.25 USD | -0.53% |
|
-7.34% | +29.88% |
| May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
| May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,628 | 1,855 | 2,115 | 4,720 | 6,146 | - | - |
| Enterprise Value (EV) 1 | 2,628 | 1,278 | 1,470 | 2,867 | 4,773 | 5,300 | 5,891 |
| P/E ratio | -19.7 x | -9.79 x | -7.73 x | -7.43 x | -11.9 x | -10.5 x | -10.2 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 61.1 x | 63.1 x | 59.8 x | 408 x | 2,811 x | 2,304 x | 254 x |
| EV / Revenue | 61.1 x | 43.5 x | 41.6 x | 248 x | 2,183 x | 1,987 x | 243 x |
| EV / EBITDA | -24.3 x | -6.91 x | -5.81 x | -5.96 x | -8.12 x | -8.21 x | -8.54 x |
| EV / FCF | -25.5 x | -8.31 x | -6.25 x | -8 x | -9.6 x | -11 x | -12.1 x |
| FCF Yield | -3.92% | -12% | -16% | -12.5% | -10.4% | -9.1% | -8.28% |
| Price to Book | 4.58 x | 3.1 x | 3.14 x | 1.78 x | 4.47 x | 6.15 x | 11.9 x |
| Nbr of stocks (in thousands) | 66,380 | 73,687 | 88,791 | 164,565 | 164,986 | - | - |
| Reference price 2 | 39.59 | 25.17 | 23.82 | 28.68 | 37.25 | 37.25 | 37.25 |
| Announcement Date | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 50.04 | 42.98 | 29.39 | 35.38 | 11.58 | 2.186 | 2.668 | 24.24 |
| EBITDA 1 | - | -108.1 | -184.9 | -253.2 | -481.1 | -588 | -645.4 | -689.9 |
| EBIT 1 | -54.12 | -110.7 | -188 | -258.3 | -487.2 | -588 | -634.1 | -651.3 |
| Operating Margin | -108.15% | -257.54% | -639.7% | -730.01% | -4,207.12% | -26,890.88% | -23,770.7% | -2,686.59% |
| Earnings before Tax (EBT) 1 | -52.04 | -108.5 | -187.1 | -249.1 | -439.9 | -509 | -583.2 | -605.8 |
| Net income 1 | -61.9 | -110.4 | -187.1 | -248.7 | -436.4 | -509.9 | -580.6 | -615.3 |
| Net margin | -123.7% | -256.8% | -636.58% | -702.95% | -3,768.28% | -23,321.92% | -21,765.15% | -2,538.16% |
| EPS 2 | -1.049 | -2.010 | -2.570 | -3.080 | -3.860 | -3.132 | -3.542 | -3.657 |
| Free Cash Flow 1 | -52.2 | -103 | -153.7 | -235.2 | -358.3 | -497 | -482.2 | -487.8 |
| FCF margin | -104.32% | -239.62% | -522.99% | -664.83% | -3,094.14% | -22,730.39% | -18,077.71% | -2,012.05% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.46 | 7.578 | 9.116 | 3.356 | 15.33 | 7.014 | 3.824 | - | 0.742 | - | 0.4091 | 0.4091 | 0.4091 | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | -178.4 | - | -146.1 | -154 | -161.6 | -169.6 | -171 |
| EBIT 1 | -52.91 | -57.95 | -62.09 | -76.53 | -61.71 | -75.16 | -108.8 | -123.2 | -180 | -140.9 | -143.9 | -150.6 | -153.9 | -160 | -162.2 |
| Operating Margin | -559.33% | -764.7% | -681.1% | -2,280.48% | -402.52% | -1,071.53% | -2,845.11% | - | -24,256.47% | - | -35,183.22% | -36,817.04% | -37,632.13% | - | - |
| Earnings before Tax (EBT) 1 | -52.68 | -57.65 | -61.22 | -73.63 | -56.63 | -68.1 | -98.3 | -112.3 | -161.2 | -116 | -124.5 | -131.6 | -135.4 | -143.8 | -146.2 |
| Net income 1 | -52.68 | -57.65 | -61.22 | -73.33 | -56.51 | -68.1 | -98.3 | -108.4 | -161.5 | -116 | -125.2 | -131.6 | -135.4 | -144 | -147.6 |
| Net margin | -556.83% | -760.72% | -671.58% | -2,185.01% | -368.6% | -970.89% | -2,570.55% | - | -21,770.49% | - | -30,605.83% | -32,170.44% | -33,100.49% | - | - |
| EPS 2 | -0.7100 | -0.7800 | -0.8200 | -0.8700 | -0.6300 | -0.7200 | -0.9200 | -0.9900 | -1.140 | -0.7000 | -0.7591 | -0.7987 | -0.8216 | -0.8748 | -0.9028 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/9/22 | 11/7/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/6/23 | 2/26/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 123 | - | 577 | 645 | 1,853 | 1,373 | 846 | 255 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.2 | -103 | -154 | -235 | -358 | -497 | -482 | -488 |
| ROE (net income / shareholders' equity) | - | -68.5% | -34.7% | -38.6% | -34.8% | -30.8% | -50.2% | -100% |
| ROA (Net income/ Total Assets) | -31.7% | -28% | -28.7% | -32.1% | -30.4% | -28% | -36.4% | -52.8% |
| Assets 1 | 195.6 | 394 | 652.7 | 774.5 | 1,436 | 1,821 | 1,595 | 1,164 |
| Book Value Per Share 2 | -2.590 | 8.650 | 8.130 | 7.580 | 16.10 | 8.340 | 6.060 | 3.130 |
| Cash Flow per Share 2 | - | - | - | - | -3.100 | - | 7.320 | - |
| Capex 1 | 2.59 | 2.93 | 6.53 | 10.8 | 7.73 | 8.15 | 11.3 | 12.5 |
| Capex / Sales | 5.17% | 6.82% | 22.21% | 30.57% | 66.74% | 372.92% | 424.73% | 51.7% |
| Announcement Date | 3/30/20 | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
37.25
USD
Average target price
44.82
USD
Spread / Average Target
+20.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.88% | 6.15B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- RVMD Stock
- Financials Revolution Medicines, Inc.
